International Journal of Rheumatic Diseases最新文献

{"title":"Is IgG4-Related Disease a Potential Risk Factor for Multiple Malignancies?","authors":"Rahime Duran, Derya Yıldırım, Rıza Can Kardaş, İbrahim Vasi, Hamit Küçük, Abdulsamet Erden","doi":"10.1111/1756-185X.70286","DOIUrl":"https://doi.org/10.1111/1756-185X.70286","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Using an Extended Set of Clinical Variables: An Unmet Need","authors":"Nam Nguyen, Sasha Bernatsky, Ines Colmegna, Claudie Berger, Nathalie Carrier, Hugues Allard-Chamard, Patrick Liang, Sophie Roux, Gilles Boire, Marie Hudson","doi":"10.1111/1756-185X.70281","DOIUrl":"https://doi.org/10.1111/1756-185X.70281","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Kidney Function Preservation in Nonresponders to Initial Induction Therapy for Lupus Nephritis","authors":"Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong","doi":"10.1111/1756-185X.70282","DOIUrl":"https://doi.org/10.1111/1756-185X.70282","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Isolated Osteoarticular Sarcoidosis: Emphasizing the Importance of Differential Diagnosis","authors":"Zeynep Özge Özdemir, Serdar Can Güven, Orhan Kücükşahin","doi":"10.1111/1756-185X.70290","DOIUrl":"https://doi.org/10.1111/1756-185X.70290","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 Comprehensive Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Management of Sjögren's Syndrome","authors":"Galymzhan Togizbayev,&nbsp;Bakyt Aubakirova,&nbsp;Dina Dilmanova,&nbsp;Lina Zaripova,&nbsp;Aida Tabenova,&nbsp;Karlygash Karina,&nbsp;Larisa Makalkina","doi":"10.1111/1756-185X.70272","DOIUrl":"https://doi.org/10.1111/1756-185X.70272","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sjögren's syndrome (SjS) is a chronic autoimmune disease characterized by exocrine gland dysfunction and systemic involvement. Although international guidelines exist, regional adaptations are necessary to address specific healthcare settings. In 2024, the Qazaq College of Rheumatology (QCR) developed comprehensive national recommendations for the diagnosis and management of SjS in Kazakhstan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A panel of national experts reviewed and synthesized international guidelines (EULAR, ACR, and BSR) alongside local clinical data to create tailored diagnostic and therapeutic algorithms. Special emphasis was placed on the management of severe systemic manifestations and accessibility of therapies within Kazakhstan's healthcare system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The QCR recommendations propose a structured diagnostic approach combining clinical features, serological markers, and minor salivary gland biopsy. Treatment strategies emphasize non-pharmacological measures, symptomatic therapies, and immunomodulatory agents for systemic disease. Rituximab is prioritized as the first-line biologic for refractory severe extraglandular manifestations. A national registry for SjS is proposed to monitor implementation and outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These guidelines aim to standardize the diagnosis and management of Sjögren's syndrome across Kazakhstan, improve patient outcomes, and support further research initiatives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Rapid Progression of Pulmonary Interstitial Fibrosis Combined With Pneumocystis Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tocilizumb","authors":"Xiaochen Li,&nbsp;Qianyu Guo,&nbsp;Dan Ma,&nbsp;Shan Wu,&nbsp;Liyun Zhang,&nbsp;Ke Xu","doi":"10.1111/1756-185X.70284","DOIUrl":"https://doi.org/10.1111/1756-185X.70284","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety and Efficacy of JAK Inhibitors: Have We Found the Right Pathway?","authors":"Lei Wang,&nbsp;Yung-Heng Lee,&nbsp;Xin-lei Yang,&nbsp;Po-Cheng Shih,&nbsp;Jin-fang Gao,&nbsp;Li-yun Zhang","doi":"10.1111/1756-185X.70130","DOIUrl":"https://doi.org/10.1111/1756-185X.70130","url":null,"abstract":"<p>Elderly patients with autoimmune diseases require long-term medication and physiotherapy, which also involves lifestyle modification. Ongoing follow-up and treatment lead to frequent consumption of healthcare resources, including outpatient visits, hospitalization, examinations, and medicines, putting financial pressure on patients and families. At the same time, the loss of patients' labor force has socioeconomic implications. Among drug therapies, Janus kinase (JAK) inhibitors are an important class of drugs that have shown significant efficacy in the treatment of autoimmune and inflammatory diseases. However, the issue of selectivity of these drugs has been a challenge in clinical application. Nonselective JAK inhibitors may lead to adverse events, including infections, hematologic alterations, cardiovascular and thrombotic risks, and possible malignancy risks, limiting their use. Nevertheless, the significance of selectivity in achieving effective treatment responses and minimizing adverse events remains uncertain.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis","authors":"Hironobu Kosugiyama,&nbsp;Shuji Asai,&nbsp;Kenya Terabe,&nbsp;Tomonori Kobayakawa,&nbsp;Yutaka Yoshioka,&nbsp;Tatsuo Watanabe,&nbsp;Toshihisa Kojima,&nbsp;Yasumori Sobue,&nbsp;Takefumi Kato,&nbsp;Takayoshi Fujibayashi,&nbsp;Yuji Hirano,&nbsp;Tsuyoshi Nishiume,&nbsp;Mihoko Kato,&nbsp;Yasuhide Kanayama,&nbsp;Toki Takemoto,&nbsp;Masahiro Hanabayashi,&nbsp;Hiroyuki Matsubara,&nbsp;Mochihito Suzuki,&nbsp;Ryo Sato,&nbsp;Junya Hasegawa,&nbsp;Yusuke Ohno,&nbsp;Takaya Sugiura,&nbsp;Nobunori Takahashi,&nbsp;Shiro Imagama","doi":"10.1111/1756-185X.70288","DOIUrl":"https://doi.org/10.1111/1756-185X.70288","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log-rank test for between-group comparisons. Differences in Clinical Disease Activity Index (CDAI) score from baseline were assessed using paired <i>t</i>-tests, and generalized estimating equations were used to compare the treatment groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Baseline characteristics were similar between the baricitinib and filgotinib groups. Drug retention rates due to ineffectiveness or adverse events did not differ significantly between the two groups. In the baricitinib group, the estimated mean CDAI score significantly decreased from 17.8 at baseline to 9.1 at 4 weeks, 6.6 at 12 weeks, and 6.3 at 24 weeks (<i>p</i> &lt; 0.001 for all comparisons). In the filgotinib group, the estimated mean CDAI score significantly decreased from 16.5 at baseline to 7.8 at 4 weeks, 6.2 at 12 weeks, and 6.1 at 24 weeks (<i>p</i> &lt; 0.001 for all comparisons). No significant differences were observed between the two groups in CDAI score at any time point evaluated, or in the proportion of patients who achieved CDAI remission (CDAI ≤ 2.8) at baseline (7% vs. 5%) and after 4 (23% vs. 21%), 12 (33% vs. 33%), and 24 weeks (33% vs. 37%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Baricitinib and filgotinib demonstrated comparable drug retention rates and effectiveness in reducing disease activity among patients with RA over a 24-week follow-up period.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Incidence of Rheumatoid Arthritis in Urban China: A National Population-Based Study","authors":"Mengzhuo Cao,&nbsp;Chaiquan Li,&nbsp;Mucong Li,&nbsp;Ke Lu,&nbsp;Chanyuan Wu,&nbsp;Jinxi Wang,&nbsp;Chen Wei,&nbsp;Jiuliang Zhao,&nbsp;Qian Wang,&nbsp;Xinping Tian,&nbsp;Xun Tang,&nbsp;Mengtao Li,&nbsp;Xiaofeng Zeng,&nbsp;Pei Gao","doi":"10.1111/1756-185X.70184","DOIUrl":"https://doi.org/10.1111/1756-185X.70184","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Rheumatoid arthritis (RA) is a global health problem with a heavy disease burden on both individuals and society. However, there is a lack of comprehensive nationwide data on RA prevalence, incidence, and associated economic burdens based on large-scale population studies in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A population-based study was conducted based on data from the Urban Employee Basic Medical Insurance and Urban Resident Basic Medical Insurance claims covering 380 million residents from 23 provinces in China, from 2013 to 2017. The prevalence and incidence rates of RA stratified by sex, age, and region were estimated by a two-stage approach with Poisson regression models. The rates were age- and sex-standardized. The associated annual costs and hospital visit times were estimated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>789 583 patients were identified with a mean age of 54.74 ± 14.72 years, of whom 61.25% were female. The standardized prevalence rate of RA in China in 2017 was 334.35 (95% CI 288.20–383.92) per 100 000 people with 443.97 (95% CI 368.23–526.76) and 242.25 (95% CI 188.87–302.24) per 100 000 people in females and males. The prevalence increased at an average annual rate of 21.79%. The incidence rate in 2017 was 128.71 (95% CI, 101.69–158.91) per 100 000 person-years. The prevalence and incidence rates peaked at 65–74 years old in both sexes. The prevalence and incidence rates were lower in Southern China compared to other regions. The average annual cost per capita for RA patients was estimated to be US$907.78.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The high and rising prevalence, incidence, and medical costs of RA impose a substantial societal burden. Distinct patterns in prevalence across geographic regions require further research for underlying causes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease","authors":"Dilara Bulut Gökten,&nbsp;Mehmet Engin Tezcan,&nbsp;Burcu Yağız,&nbsp;Abdulsamet Erden,&nbsp;Gezmiş Kimyon,&nbsp;Nazife Şule Yaşar Bilge,&nbsp;Levent Kılıç,&nbsp;Belkıs Nihan Coşkun,&nbsp;Emine Duygu Ersözlü,&nbsp;Orhan Küçükşahin,&nbsp;Süleyman Serdar Koca,&nbsp;Emel Gönüllü,&nbsp;Muhammet Çınar,&nbsp;Servet Akar,&nbsp;Hakan Emmungil,&nbsp;Timuçin Kaşifoğlu,&nbsp;Cemal Bes,&nbsp;Aşkın Ateş,&nbsp;Yavuz Pehlivan,&nbsp;Sedat Kiraz,&nbsp;Ali İhsan Ertenli,&nbsp;Hüseyin Ediz Dalkılıç,&nbsp;Umut Kalyoncu,&nbsp;Rıdvan Mercan","doi":"10.1111/1756-185X.70274","DOIUrl":"https://doi.org/10.1111/1756-185X.70274","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The objective was to evaluate biologic disease-modifying antirheumatic drugs (DMARDs) and their side effects that hindered the continuation of treatment in a patient population diagnosed with spondyloarthritis (SpA) with a glomerular filtration rate (GFR) ≤ 60 mL/min, and to compare these side effects between patients with chronic kidney disease (CKD) and those without.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter, observational cohort study utilized data from the TReasure database, which records SpA patients in a web-based system across Türkiye. A total of 6052 patients being included. SpA patients were categorized into two main groups: non-CKD patients and CKD patients. The clinical characteristics, disease activity, treatment options, drug retention rates, reasons for drug discontinuation, and types of adverse effects were compared between the groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Biologics prescription pattern varied between CKD and non-CKD patients. Etanercept was prescribed more frequently (53.1%) in CKD patients. Regarding the number of side effects and drug discontinuations in CKD patients, no statistically significant differences were found between the non-CKD and CKD groups for any of the bDMARDs (adalimumab, etanercept, golimumab, infliximab, ustekinumab, secukinumab, and certolizumab). No statistically significant differences were observed in the duration of drug retention based on CKD status for bDMARDs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study offers preliminary evidence supporting the effective and safe use of bDMARDs in patients with SpA and CKD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70274","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}